Align Technology (ALGN) Stock Looks Cheap On Cash Flow Yet Fair On Earnings

Simply Wall St · 1d ago

Align Technology stock has delivered a steep 73.4% decline over the past five years, yet the current intrinsic value estimate from a Discounted Cash Flow (DCF) model still points to meaningful upside compared with where shares trade today. At the same time, broader valuation checks and earnings multiples suggest pricing that is closer to fair than outright distressed.

  • The share price is down 73.4% over five years, which frames the current valuation debate around whether this is a long term reset or an opportunity after a major drawdown.
  • Recent record revenue and a larger share buyback plan can support the case that cash flows may grow from here, while ongoing competitive and legal risks, even with a recent patent win in China, may limit how much value investors are willing to ascribe to those future cash flows.
  • Align Technology scores 3 out of 6 on Simply Wall St's broader valuation checks, which is a mixed picture rather than a clear bargain or clear overvaluation. You can see the detail on the 3/6 score here.

The issue now is whether Align Technology's current price already reflects most of what the intrinsic value estimate and recent business momentum suggest, or if there is still a margin of safety.

Align Technology delivered 27.3% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Is Align Technology a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach here values Align Technology based on projected future free cash flows to equity. Align Technology generated around $639 million in free cash flow over the last twelve months, and the 2 Stage Free Cash Flow to Equity model assumes these cash flows continue to grow rather than contract. On that basis, the model points to an estimated intrinsic value of about $311 per share.

Compared with the current share price, this intrinsic value implies the stock is about 41.6% undervalued according to the model. The recent record Q2 2026 revenue and the expanded share buyback program are cited as reasons why cash flows in the model are treated as growing rather than shrinking. Despite that backdrop, the market price remains below the level indicated by the Discounted Cash Flow (DCF) estimate.

Overall, the Discounted Cash Flow (DCF) workup indicates Align Technology stock currently screens as undervalued according to this model.

Our Discounted Cash Flow (DCF) analysis suggests Align Technology is undervalued by 41.6%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

ALGN Discounted Cash Flow as at Aug 2026
ALGN Discounted Cash Flow as at Aug 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Align Technology.

Where Does Align Technology Sit on Earnings?

The P/E ratio suits Align Technology because earnings remain a key anchor for how investors think about this business. Align Technology currently trades on a P/E of about 31.1x, which is above the Medical Equipment industry average of roughly 26.2x, yet slightly below the peer group average of about 33.7x.

Simply Wall St’s fair P/E for Align Technology is about 30.0x. That is very close to the current multiple, which suggests the stock is priced in line with what this framework expects once it weighs the company’s growth profile, margins, size and risk factors. The result is a valuation that looks neither clearly cheap nor clearly stretched on earnings alone.

On balance, Align Technology appears roughly fairly valued based on its current P/E multiple.

NasdaqGS:ALGN P/E Ratio as at Aug 2026
NasdaqGS:ALGN P/E Ratio as at Aug 2026

See what the numbers say about this price — find out in our valuation breakdown.

The Align Technology Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Align Technology's valuation puzzle leaves off and ask what would need to be true about Align Technology's future growth, margins and earnings for the stock to be worth materially more or less than today's price. Each narrative connects its number to a clear view on where growth, profitability and key risks could go next, which you can revisit as new information on Align Technology arrives.

Community views on Align Technology sit far apart, with one camp focused on platform execution and the other on cost pressure and competition.

Bull case: 13% undervalued

"Bullish analysts point to multiple platform growth levers, including teen conversion, Advanced Restorative Treatment with lab partnerships, peer to peer channel expansion…"

Read the full Bull Case to see why Align Technology could be undervalued

Bear case: 17% overvalued

"Today, Align operates in a different environment. Inflation, discretionary spending pressure, and rising competition are testing whether premium orthodontics can sustain growth without sacrificing margins…"

Read the full Bear Case to see why Align Technology could be overvalued

Do you think there's more to the story for Align Technology? Head over to our Community to see what others are saying!

The Bottom Line

Align Technology looks undervalued on the Discounted Cash Flow (DCF) intrinsic value estimate, while the current P/E suggests pricing that is about right relative to peers. That mix, along with the mixed broader valuation checks, points to a stock that is not obviously mispriced but does carry a potential discount if cash flows unfold as assumed.

The key question from here is whether Align Technology can sustain the cash generation and earnings profile implied in the DCF, given ongoing competitive and legal risks. How that trade off between growth, margins and risk resolves is likely to decide whether today’s valuation ends up looking conservative or fully justified.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.